PC 786

Drug Profile

PC 786

Alternative Names: PC786

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pulmocide
  • Class Antivirals; Small molecules
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Respiratory syncytial virus infections

Most Recent Events

  • 21 Jun 2017 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in United Kingdom (Inhalation) (NCT03236233)
  • 20 Mar 2017 Pulmocide reports that it is on track to deliver POC results for PC 786 for Respiratory Syncytial Virus infections
  • 26 Oct 2016 Pharmacodynamics data from preclinical trials in Respiratory Syncytial Virus infections presented at IDWeek 2016 (IDW-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top